Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Comparison between clinical trials and real-world evidence studies on biologics for severe asthma
Francesco Menzella, Andrea Ballarin, Maria Cristina Sartor, et al.
Journal of International Medical Research (2022) Vol. 50, Iss. 11
Open Access | Times Cited: 9

Showing 9 citing articles:

Dupilumab Improves Lung Function Parameters in Pediatric Type 2 Asthma: VOYAGE Study
Leonard B. Bacharier, Theresa W. Guilbert, Constance H. Katelaris, et al.
The Journal of Allergy and Clinical Immunology In Practice (2023) Vol. 12, Iss. 4, pp. 948-959
Open Access | Times Cited: 14
Efficacy and Safety of Biologic Therapies in Severe Asthma: A Comparative Analysis of Treatment Outcomes in Pediatric and Adult Populations
Muhammad Asad, Yasser Osman, Saeed Nazari Soltan Ahmad, et al.
Indus journal of bioscience research. (2025) Vol. 3, Iss. 3, pp. 329-335
Closed Access
Baseline Characteristics of Patients Enrolled in Clinical Trials of Biologics for Severe Asthma as Potential Predictors of Outcomes
Francesco Menzella
Journal of Clinical Medicine (2023) Vol. 12, Iss. 4, pp. 1546-1546
Open Access | Times Cited: 6
Anti-IL-5 and anti-IL-5R biologics for severe asthma. Are there any differences in their effects?
Paula Granda, Elena Villamañán, Carlos Carpio, et al.
Journal of Asthma (2024) Vol. 61, Iss. 8, pp. 857-866
Closed Access | Times Cited: 1
Real-world outcomes of mepolizumab for the treatment of severe eosinophilic asthma in Canada: an observational study
Kenneth R. Chapman, Kathryn Cogger, Erin Arthurs, et al.
Allergy Asthma and Clinical Immunology (2024) Vol. 20, Iss. 1
Open Access | Times Cited: 1
A comparison of the impact of anti-IL5/5R therapies in allergic versus non-allergic patients with severe eosinophilic asthma in a real-life setting
Tatiana Navarro-Cascales, Mónica Colque-Bayona, Inés Fernández-Concha, et al.
Journal of Asthma (2024), pp. 1-9
Closed Access | Times Cited: 1
Immunobiological therapy in the treatment of severe asthma
David Evangelista Barros de Oliveira, Carlos Gustavo Alves Leitão, F Falcão, et al.
Research Society and Development (2024) Vol. 13, Iss. 5, pp. e14513545933-e14513545933
Open Access
The assessment of dupilumab in children with moderate-to-severe asthma and comorbid type 2 inflammatory diseases
Tingting Shi, S.Y. Wu, Rongshan Chen, et al.
BMC Pulmonary Medicine (2024) Vol. 24, Iss. 1
Open Access
Omalizumab Transitions in Severe Asthma: Factors Influencing Switching Decisions and Timing for Optimal Response
Mona Al‐Ahmad, Asmaa Ali, Ahmed Maher
Medical Principles and Practice (2023) Vol. 32, Iss. 6, pp. 323-331
Open Access | Times Cited: 1
Page 1

Scroll to top